Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors
NCT00091806 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 86
Last updated 2009-07-10
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of two dose schedules of panitumumab in subjects with advanced solid tumors.
Conditions
Interventions
- DRUG
-
panitumumab (ABX-EGF)
6 mg/kg once every 2 weeks
- DRUG
-
Panitumumab
9 mg/kg once every 3 weeks
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-08-31
- Primary Completion
- 2006-04-30
- Completion
- 2006-10-31
More Related Trials
-
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT06131398 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT04250155 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
NCT05327946 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
NCT00813384 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT02498613 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit
NCT02211872 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
NCT05394350 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
NCT03355066 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
NCT05800964 ·Status: COMPLETED ·Phase: PHASE1
-
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
NCT00820560 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066 ·Status: RECRUITING ·Phase: PHASE1
-
Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
NCT02211859 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
NCT01188499 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
NCT02407990 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
NCT06285097 ·Status: TERMINATED ·Phase: PHASE1
-
MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)
NCT00496353 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of PM060184 in Patients With Advanced Solid Tumors
NCT01299636 ·Status: COMPLETED ·Phase: PHASE1
-
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
NCT03621982 ·Status: TERMINATED ·Phase: PHASE1
-
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
NCT03166631 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
NCT05155332 ·Status: SUSPENDED ·Phase: PHASE1
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
NCT05761223 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
NCT02503423 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
NCT06331559 ·Status: TERMINATED ·Phase: PHASE1
-
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
NCT02222922 ·Status: COMPLETED ·Phase: PHASE1